Literature DB >> 33822250

[Current WHO classification of the female genitals : Many new things, but also some old].

Doris Mayr1, Elisa Schmoeckel2, Anne Kathrin Höhn3, Grit Gesine Ruth Hiller3, Lars-Christian Horn3.   

Abstract

The new WHO classification of tumors of the female genitalia entails some changes, especially those of prognostic and therapeutic relevance: there is a return to the term borderline tumor. Implants are again subdivided into noninvasive implants of the epithelial or desmoplastic type as before. Invasive extraovarian implants are classified as low-grade serous carcinoma (LGSC). Former seromucinous carcinomas are now classified as endometrioid carcinomas (seromucinous subtype). New entities of ovarian carcinomas are mesonephric-like adenocarcinoma, undifferentiated and dedifferentiated carcinoma, and mixed carcinoma. The classification of neuroendocrine neoplasms is analogous to that of pulmonary and gastrointestinal neuroendocrine neoplasms, regardless of their location. Endometrioid endometrial carcinoma can be classified into four molecular subtypes, which have significant prognostic significance. New subtypes include mucinous carcinoma of the intestinal type and mesonephric-like adenocarcinoma. Stromasarcomas of the endometrium are further subclassified based on specific molecular alterations. Adenocarcinomas (ACs) and squamous cell carcinomas (PECs) of the lower female genital tract are distinguished from HPV-associated and HPV-independent carcinomas. Block-like staining for p16 is the accepted surrogate immunohistochemical marker. Grading has not been reported for PEC. For HPV-associated AC of the cervix uteri, prognostic assessment is based on the pattern of invasion (so-called Silva pattern). Serous carcinomas in the cervix uteri are endometrial carcinomas with cervical infiltration.

Entities:  

Keywords:  Grading; HPV; Molecular diagnostics and subtyps; Silva pattern; p16

Mesh:

Substances:

Year:  2021        PMID: 33822250     DOI: 10.1007/s00292-021-00933-w

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  43 in total

1.  The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology.

Authors:  Teresa M Darragh; Terence J Colgan; J Thomas Cox; Debra S Heller; Michael R Henry; Ronald D Luff; Timothy McCalmont; Ritu Nayar; Joel M Palefsky; Mark H Stoler; Edward J Wilkinson; Richard J Zaino; David C Wilbur
Journal:  Arch Pathol Lab Med       Date:  2012-06-28       Impact factor: 5.534

Review 2.  [The 2019 FIGO classification for cervical carcinoma-what's new?]

Authors:  L-C Horn; C E Brambs; S Opitz; U A Ulrich; A K Höhn
Journal:  Pathologe       Date:  2019-11       Impact factor: 1.011

3.  International Endocervical Adenocarcinoma Criteria and Classification (IECC): correlation with adverse clinicopathological features and patient outcome.

Authors:  Anjelica Hodgson; Ekaterina Olkhov-Mitsel; Brooke E Howitt; Marisa R Nucci; Carlos Parra-Herran
Journal:  J Clin Pathol       Date:  2019-01-24       Impact factor: 3.411

4.  Ontogenetic anatomy of the distal vagina: relevance for local tumor spread and implications for cancer surgery.

Authors:  Michael Höckel; Lars-Christian Horn; Romana Illig; Nadja Dornhöfer; Helga Fritsch
Journal:  Gynecol Oncol       Date:  2011-05-31       Impact factor: 5.482

5.  Mesonephric-like Carcinoma of the Endometrium: A Subset of Endometrial Carcinoma With an Aggressive Behavior.

Authors:  Elizabeth D Euscher; Roland Bassett; Dzifa Y Duose; Chieh Lan; Ignacio Wistuba; Lois Ramondetta; Preetha Ramalingam; Anais Malpica
Journal:  Am J Surg Pathol       Date:  2020-04       Impact factor: 6.394

6.  A rare case of HPV-negative cervical squamous cell carcinoma.

Authors:  Shauna Casey; Ian Harley; Jackie Jamison; Anco Molijn; Henk van den Munckhof; W Glenn McCluggage
Journal:  Int J Gynecol Pathol       Date:  2015-03       Impact factor: 2.762

7.  Myxoid leiomyosarcoma of the uterus.

Authors:  David M Burch; Fattaneh A Tavassoli
Journal:  Histopathology       Date:  2011-12       Impact factor: 5.087

8.  YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy.

Authors:  Matthew L Hemming; Andrew J Wagner; Marisa R Nucci; Sarah Chiang; Lu Wang; Martee L Hensley; Suzanne George
Journal:  Gynecol Oncol       Date:  2017-04-05       Impact factor: 5.482

9.  Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.

Authors:  Amanda N Fader; Dana M Roque; Eric Siegel; Natalia Buza; Pei Hui; Osama Abdelghany; Setsuko K Chambers; Angeles Alvarez Secord; Laura Havrilesky; David M O'Malley; Floor Backes; Nicole Nevadunsky; Babak Edraki; Dirk Pikaart; William Lowery; Karim S ElSahwi; Paul Celano; Stefania Bellone; Masoud Azodi; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Peter E Schwartz; Alessandro D Santin
Journal:  J Clin Oncol       Date:  2018-03-27       Impact factor: 44.544

10.  Human papillomavirus, p16(INK4A), and Ki-67 in relation to clinicopathological variables and survival in primary carcinoma of the vagina.

Authors:  K Hellman; D Lindquist; C Ranhem; E Wilander; S Andersson
Journal:  Br J Cancer       Date:  2014-02-13       Impact factor: 7.640

View more
  1 in total

Review 1.  [Revised German guidelines on the diagnosis and treatment of carcinoma of the uterine cervix-what's new for pathologists in 2021?]

Authors:  Lars-Christian Horn; Matthias W Beckmann; Markus Follmann; Martin C Koch; Monika Nothacker; Birgit Pöschel; Frederik Stübs; Dietmar Schmidt; Anne Kathrin Höhn
Journal:  Pathologie (Heidelb)       Date:  2022-02-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.